Skip to main content
TNYA
NASDAQ Life Sciences

Tenaya Therapeutics terminates GMMC lease, incurring $2M cost for long-term savings

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$0.787
Mkt Cap
$170.756M
52W Low
$0.532
52W High
$2.35
52W Position info
48% above low
Off High info
67% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

TNYA sits 48% above its 52-week low of $0.532.

Summary

Tenaya Therapeutics terminated its lease for its Genetic Medicines Manufacturing Center, incurring a $2.04 million one-time cost but eliminating future lease obligations and shifting to a contract manufacturing model.


Key Events · Financing and Capital Events · TNYA

  • Lease Termination

    Tenaya Therapeutics terminated its lease for the 94,046 sq ft Genetic Medicines Manufacturing Center (GMMC Facility) in Union City, California, effective August 31, 2026, instead of July 2031.

  • Financial Impact

    The termination involved forfeiting a $1.75 million security deposit and paying a $294,200 termination fee, totaling approximately $2.04 million in one-time costs.

  • Strategic Shift

    The company plans to transfer its AAV manufacturing process to a contract development manufacturing organization (CDMO), having decommissioned the facility in 2025 to reduce costs.


Analysis · TNYA · Life Sciences

This 8-K details the financial settlement of Tenaya Therapeutics' decision to exit its Genetic Medicines Manufacturing Center, a move initiated in 2025 to reduce costs. While the company incurs a $2.04 million one-time expense, it eliminates a lease obligation that was set to run until 2031. This strategic shift to a contract manufacturing model aims to improve operational flexibility and reduce fixed costs, which is a positive step for a company facing Nasdaq delisting risk.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TNYA was trading at $0.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $170.8M. The 52-week trading range was $0.53 to $2.35. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TNYA - Latest Insights

TNYA
Nov 04, 2026, 4:41 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.377
Real-time Price: $0.31945 info
Change: -$0.05755 (-15%) info
Market Cap: $72.664M info
TNYA
Nov 04, 2026, 4:13 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.385
Real-time Price: $0.31945 info
Change: -$0.06555 (-17%) info
Market Cap: $72.664M info
TNYA
Oct 13, 2026, 4:42 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.530
Real-time Price: $0.31945 info
Change: -$0.21055 (-40%) info
Market Cap: $72.664M info
TNYA
Sep 14, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.6395
Real-time Price: $0.31945 info
Change: -$0.32005 (-50%) info
Market Cap: $72.664M info
TNYA
Aug 05, 2026, 4:46 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.7497
Real-time Price: $0.31945 info
Change: -$0.43025 (-57%) info
Market Cap: $72.664M info